We narrowed to 8 results for: acr.2

1. pAAV-CKIIa-stGtACR2-FusionRed (AAV1)

   Viral Prep

   #105669-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   CaMKII

   Tags

   FusionRed

   Available since

   July 17, 2018

   Availability

   Academic Institutions and Nonprofits only

2. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV1)

   Viral Prep

   #105677-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   Aug. 17, 2018

   Availability

   Academic Institutions and Nonprofits only

3. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV5)

   Viral Prep

   #105677-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   Oct. 21, 2024

   Availability

   Academic Institutions and Nonprofits only

4. pAAV-CKIIa-stGtACR2-FusionRed (AAV Retrograde)

   Viral Prep

   #105669-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   CaMKII

   Tags

   FusionRed

   Available since

   July 8, 2020

   Availability

   Academic Institutions and Nonprofits only

5. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV Retrograde)

   Viral Prep

   #105677-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   July 8, 2020

   Availability

   Academic Institutions and Nonprofits only

6. pAAV-mDlx-GCaMP6f-Fishell-2 (AAV9)

   Viral Prep

   #83899-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Gordon Fishell

   Article

   Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

   Promoter

   mDlx

   Tags

   None

   Available since

   Nov. 13, 2020

   Availability

   Academic Institutions and Nonprofits only

7. pAAV-mDlx-GCaMP6f-Fishell-2 (AAV1)

   Viral Prep

   #83899-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Gordon Fishell

   Article

   Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

   Promoter

   mDlx

   Tags

   None

   Available since

   Nov. 13, 2020

   Availability

   Academic Institutions and Nonprofits only

8. pAAV-mDlx-GCaMP6f-Fishell-2 (AAV Retrograde)

   Viral Prep

   #83899-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Gordon Fishell

   Article

   Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

   Promoter

   mDlx

   Tags

   None

   Available since

   June 1, 2020

   Availability

   Academic Institutions and Nonprofits only